Submit Deal

Announced

12 Sep 2024

Completed

12 Sep 2024

BOLD and Evonik led a €35m funding round in Abolis Biotechnologies.

Synopsis

BOLD and Evonik led a €35m funding round in Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms, with participation from DeepTech & Climate Fonds, Clay Capital, ICOS Capital and Liberset.

Principals

target

Abolis Biotechnologies

bidder

Evonik Venture Capital

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

Sort

Seller Team (5)

cyrille pauthenier

CEO at ABOLIS BIOTECHNOLOGIES

Manager

target

Deal

£ 30 M

Total Value

bruno arabian

Partner at Ulysse Communication

PR Consultant

target

Deals

£ 129 M

Total Value

philippe leopold

Partner at Spayne Lindsay & Co

Financial Advisor

target

Deals

£ 7.18 B

Total Value

nicholas entz

Ulysse Communication

PR Consultant

target

Deal

£ 30 M

Total Value

alexandre weill

Director at Spayne Lindsay & Co

Financial Advisor

target

Deals

£ 30 M

Total Value

Bidder Team (6)

bernhard mohr

Managing Director at EVONIK VENTURE CAPITAL

Manager

bidder

Deals

£ 67 M

Total Value

matthieu vermersch

Founder at EVONIK VENTURE CAPITAL

Manager

bidder

Deals

£ 249 M

Total Value

samantha etienne

CEO at BUSINESS OPPORTUNITIES FOR L'ORÉAL DEVELOPMENT (BOLD)

Investor

bidder

Deal

£ 30 M

Total Value

damien bourel

Co-Founder at LIBERSET

Manager

bidder

Deal

£ 30 M

Total Value

tobias faupel

Managing Director at DEEPTECH & CLIMATE FONDS

Manager

bidder

Deal

£ 30 M

Total Value

peter van gelderen

Managing Partner at ICOS CAPITAL

Manager

bidder

Deal

£ 30 M

Total Value

By continuing, you agree to our Terms & Conditions and our Data Privacy Policy